Nuvectis Pharma, Inc. (NVCT) Stock Profile — Insider Trades & Financials

Net Income-$7.3M

EPS$-1.32

Market Cap$215.6M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Ron Bentsur

CEO & Executive Director

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Founded: 2020
Employees: 13
Headquarters: Fort Lee, New Jersey, United States

⚡

Core Efficiency

ROE?

-39.72%

ROA?

-23.07%

D/E Ratio?

0.72

📊

Profitability Ratios

Current Ratio?

2.38

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Jul 7, 2026 (in 89 days)

Annual Report (10-K) — Based on filing pattern

Jul 7, 2026

Predicted10-K

Feb 11, 2026

10-KQ4 20255d after period end

Feb 11, 2026

10-KFY 202542d after period end

Nov 4, 2025

10-QQ3 20253d after period end

Aug 5, 2025

10-QQ2 20254d after period end

May 6, 2025

10-QQ1 20255d after period end

Feb 25, 2025

10-KQ4 20244d after period end

Feb 25, 2025

10-KFY 202556d after period end

Nov 5, 2024

10-QQ3 20244d after period end

Loading company sections...

Nuvectis Pharma, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness